New Study Published in the Journal of Rheumatology Examines Quality of Life and Disability in Treatment Failure Gout Patients
EAST BRUNSWICK, N.J., May 5 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the print publication of the Savient-supported longitudinal observational (non-interventional) study of patients with treatment failure gout (TFG). The objective of the study was to determine the baseline characteristics and natural history of the disease in these patients, who are without treatment options, when under the care of a Board Certified Rheumatologist.
The study is the first to evaluate the quality of life in patients with treatment failure gout and appears in the May issue of the Journal of Rheumatology. TFG is defined as advanced gout in patients where conventional therapy is contraindicated or has been ineffective.
"Our study examined some of the most difficult to treat gout patients, many of whom regularly experience excruciating pain and struggle with co-morbid health disorders like metabolic and cardiovascular disease," said John S. Sundy, MD, PhD, Division of Rheumatology at
Treatment failure gout was shown to be associated with poor health-related quality of life and significant disability. Validated survey instruments for the assessment of patient-reported quality of life were used in this study which included Health Assessment Questionnaire-Disability Index and the SF-36. The TFG patients that were
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved